Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Biomarkers and Early Detection Research

Abstract A23: PSA testing and prostate cancer mortality in an Asian population: Linking prevalence of elevated PSA and mortality rate

Po‐Huang Chiang and Chi‐Pang Wen
Po‐Huang Chiang
National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chi‐Pang Wen
National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.PREV-09-A23 Published January 2010
  • Article
  • Info & Metrics
Loading
Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Dec 6–9, 2009; Houston, TX

Abstract

Background: In Asian populations, prostate cancer mortality (PCM) has been increasing with the increasing use of PSA testing.

Objectives: 1) To establish prevalence of elevated PSA at different cutpoints in Taiwan and to assess the predictive relationship of PSA with PCM. 2) To compare PCM between those with PSA tested and not tested from a cohort study.

Methods: Among the cohort, 231,937, who received standard medical screening examination between 1994 and 2006 at a private screening clinic, 46,951 subjects, aged at least 50 years old, had PSA test results. Age and education were adjusted to those of Taiwan to arrive at national PSA prevalence. PCM was compared between the PSA untested (38,596) and PSA tested group (24,176), with the latter including those with a self‐reported history of prostate cancer (1,675).

Results: National prevalence of PSA was 8.8% (threshold at 4) and 1.9% (threshold at 10). With national mortality rate at 30.1/100,000, the chance of dying in ten years was 3.4%, 15.8% or 27.9% among those above threshold at 4, 10, or 15, respectively, yielding false positives rates, with mortality as the outcome, 96.4%, 84.2% or 72.1%, and false negative rates, 12%, 33% or 50%, respectively. Having PSA tested, when compared with not tested, was not associated with decreased mortality from prostate cancer, even though PSA tested group, a higher educational class, had significantly decreased mortality from all cause. Increasing PSA levels were associated with increasing HRs.

Conclusion: PSA value above standard threshold of 4 is common in this Asian population (one out of 11 for age 50 and older), but only one in 29 tested positive was expected to die from prostate cancer within the next 10 years. This 10‐year probability increased when threshold was 10 (1/6) but was still low. The high false positive rate of PSA (97%) and the harm associated with intervention among Asians should be communicated to the elderly patients, in view of the particularly low mortality rate of this cancer.

Citation Information: Cancer Prev Res 2010;3(1 Suppl):A23.

  • Copyright © January 7, 2010, American Association for Cancer Research
Previous
Back to top
January 2010
Volume 3, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A23: PSA testing and prostate cancer mortality in an Asian population: Linking prevalence of elevated PSA and mortality rate
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A23: PSA testing and prostate cancer mortality in an Asian population: Linking prevalence of elevated PSA and mortality rate
Po‐Huang Chiang and Chi‐Pang Wen
Cancer Prev Res January 7 2010 (3) (1 Supplement) A23; DOI: 10.1158/1940-6207.PREV-09-A23

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A23: PSA testing and prostate cancer mortality in an Asian population: Linking prevalence of elevated PSA and mortality rate
Po‐Huang Chiang and Chi‐Pang Wen
Cancer Prev Res January 7 2010 (3) (1 Supplement) A23; DOI: 10.1158/1940-6207.PREV-09-A23
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Biomarkers and Early Detection Research

  • Abstract PR10: Identification of novel candidate serum metabolite biomarkers for distinguishing between gastro-esophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma
  • Abstract CN01-02: Instrumenting the healthcare enterprise for discovery research
  • Abstract CN01-01: Big challenges of big data: Biomedical science in the petabyte era
Show more Biomarkers and Early Detection Research

Poster Presentations - Proffered Abstracts

  • Abstract A54: Case-based causality: An application of artificial intelligence to environmental carcinogenesis
  • Abstract A25: Arsenic and benzo(a)pyrene coexposure synergizes in inducing cancer stem cell-like property and lung tumorigenesis
  • Abstract A03: Preconception paternal DDT exposure and programming of metabolic dysfunction and breast cancer in offspring
Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Cancer Surveillance and Screening

  • Abstract B18: Personalizing the frequency of mammography: Cost effectiveness of screening mammography for women age 40 to 80 by breast density and other risk factors
  • Abstract B19: Evaluation of progression of cirrhosis to hepatocellular carcinoma using site-specific protein glycosylation analysis.
  • Abstract A22: Spirometric surveillance for premalignant and malignant bronchial lesions
Show more Poster Presentations - Cancer Surveillance and Screening
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement